InvestSMART

PYC Therapeutics Limited (ASX: PYC) - Announcements

Current share price for PYC : $1.645 0.015 (0.92%)+

ASX company news and announcements for PYC Therapeutics Limited (PYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PYC Therapeutics Limited (PYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PYC Therapeutics Limited (PYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PYC Therapeutics Limited (PYC)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$1,620 Presentation of Ophthalmology Clinical Trial Data at ARVO 4 May 2026 9:14AM $1.225 $1.645 risen by 34.29%
$1,620 Exercise of Options and Cleansing Notice 28 Apr 2026 6:44PM $1.305 $1.645 risen by 26.05%
$1,620 Application for quotation of securities - PYC 28 Apr 2026 6:34PM $1.305 $1.645 risen by 26.05%
$1,620 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2026 9:12AM $1.310 $1.645 risen by 25.57%
$1,620 Orphan Drug Designation Granted for RP11 by EMA 27 Apr 2026 9:48AM $1.295 $1.645 risen by 27.03%
$1,620 ADOA Program - SRC Approve Progression to Multi-Dose Study 15 Apr 2026 10:53AM $1.210 $1.645 risen by 35.95%
$1,620 Change in substantial holding 1 Apr 2026 8:25PM $1.165 $1.645 risen by 41.20%
$1,620 Change of Director's Interest Notice RH 27 Mar 2026 1:17PM $1.113 $1.645 risen by 47.87%
$1,620 PKD - Presentation at World Congress of Nephrology 27 Mar 2026 9:58AM $1.170 $1.645 risen by 40.60%
$1,620 ADOA Program - Presentation at NANOS 2026 24 Mar 2026 9:01AM $1.200 $1.645 risen by 37.08%
$1,620 Regulatory Alignment on Registrational Trial Requirements 16 Mar 2026 9:19AM $1.415 $1.645 risen by 16.25%
$1,620 Change of Director's Interest Notice RH IC 10 Mar 2026 6:41PM $1.470 $1.645 risen by 11.90%
$1,620 Application for quotation of securities - PYC 9 Mar 2026 7:55PM $1.480 $1.645 risen by 11.15%
$1,620 Application for quotation of securities - PYC 6 Mar 2026 9:46AM $1.485 $1.645 risen by 10.77%
$1,620 Joint Company Secretary Appointment 4 Mar 2026 7:11PM $1.470 $1.645 risen by 11.90%
$1,620 Completion of Retail Entitlement Offer 4 Mar 2026 9:29AM $1.485 $1.645 risen by 10.77%
$1,620 PKD Clinical Trial - Approval to Escalate Dosing 27 Feb 2026 8:04AM $1.495 $1.645 risen by 10.03%
$1,620 Change in substantial holding 25 Feb 2026 9:35AM $1.490 $1.645 risen by 10.40%
$1,620 2026 Q1 Investor Update 24 Feb 2026 9:18AM $1.500 $1.645 risen by 9.67%
$1,620 Half Yearly Report and Accounts 23 Feb 2026 6:47PM $1.500 $1.645 risen by 9.67%
$1,620 Application for quotation of securities - PYC 18 Feb 2026 9:47AM $1.490 $1.645 risen by 10.40%
$1,620 Becoming a substantial holder 13 Feb 2026 12:29PM $1.485 $1.645 risen by 10.77%
$1,620 Cleansing Notice under Section 708A(5)(e) 12 Feb 2026 11:39AM $1.495 $1.645 risen by 10.03%
$1,620 Application for quotation of securities - PYC 11 Feb 2026 11:45AM $1.495 $1.645 risen by 10.03%
$1,620 Despatch of Retail Offer Booklet 9 Feb 2026 1:32PM $1.475 $1.645 risen by 11.53%

51 - 75 of 961 results

Page 3 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.